Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Tracking Information
First Submitted Date ICMJE	November 1, 1999
First Posted Date ICMJE	January 27, 2003
Last Update Posted Date	July 3, 2013
Study Start Date ICMJE	September 1995
Actual Primary Completion Date	June 2003 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE	Not Provided
Original Primary Outcome Measures ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00002697 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE	Not Provided
Original Secondary Outcome Measures ICMJE	Not Provided
Current Other Outcome Measures ICMJE	Not Provided
Original Other Outcome Measures ICMJE	Not Provided
Descriptive Information
Brief Title ICMJE	Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
Official Title ICMJE	HIGH DOSE CHEMORADIOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY REFRACTORY, RELAPSED AND POOR PROGNOSIS NON-HODGKIN'S LYMPHOMA
Brief Summary	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy and peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy plus radiation therapy followed by peripheral stem cell transplantation in patients with refractory or recurrent non-Hodgkin's lymphoma.
Detailed Description	OBJECTIVES: Determine the efficacy of mobilization using filgrastim (G-CSF) with or without standard-dose ifosfamide, carboplatin, and etoposide (ICE), conditioning using ifosfamide and etoposide plus total body irradiation or high-dose ICE, and autologous peripheral blood stem cell (PBSC) transplantation as salvage therapy in patients with refractory, recurrent, or poor prognosis non-Hodgkin's lymphoma.; Determine the efficacy of reinduction comprising ICE followed by autologous PBSC transplantation in these patients.; Determine the ability of standard-dose ICE combined with hematopoietic growth factors to mobilize PBSC in these patients.; Determine the contamination of PBSC by lymphoma cells in patients treated with this mobilization regimen.; Determine the quality of life of patients treated with this regimen. OUTLINE: Patients are stratified according to disease status (relapsed vs refractory), lymphoma grade (low vs intermediate vs high), number of extranodal sites, serum lactic dehydrogenase, performance status, age, and volume of disease.; Mobilization/harvest: Patients in first or greater complete remission (CR) are treated on regimen A, whereas patients with recurrent or refractory disease are treated on regimen B. Regimen A: Patients with poor prognosis intermediate-grade lymphoma (IGL) in first CR or IGL or low-grade lymphoma (LGL) in second or greater CR receive mobilization with filgrastim (G-CSF) subcutaneously (SC) daily on days 1-7. Autologous peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on days 5 and 6 (and day 7 if needed). Regimen B: Patients who are currently on the MSKCC standard dose salvage therapy protocol with ifosfamide, carboplatin, and etoposide (ICE) for recurrent or refractory IGL receive additional mobilization with G-CSF after completion of the last course of ICE. Patients with recurrent or refractory IGL, immunoblastic lymphoma, or LGL who have not previously received ifosfamide and are not currently on the MSKCC standard dose salvage protocol with ICE receive ifosfamide IV and carboplatin on day 2 and etoposide IV on days 1-3 (standard-dose ICE) followed by G-CSF SC. When blood counts recover, autologous PBSC are harvested and selected for CD34+ cells. Regimens A and B: If additional hematopoietic growth factors (HGFs) become available, they may be administered concurrently with G-CSF. If inadequate CD34+ cells are collected, then autologous bone marrow is harvested.; Conditioning: Patients who are under age 60 and have not received dose-limiting radiotherapy are treated on regimen C. Patients who are age 60 and over and patients who are under age 60 and have received dose-limiting radiotherapy are treated on regimen D. Regimen C: Patients undergo hyperfractionated total body irradiation twice a day on days -10 to -7 and ifosfamide IV over 1 hour followed by etoposide IV over 23 hours on days -6 to -2. Regimen D: Patients receive ifosfamide IV over 1 hour, followed by etoposide IV over 11 hours, followed by carboplatin IV over 1 hour, followed by etoposide IV over 11 hours on days -7 to -3 (high-dose ICE). Regimens C and D: Patients with residual or relapsed disease may undergo boost radiotherapy twice a day, 5 days a week, for 1-2 weeks before conditioning or after transplantation.; Transplantation: PBSC or bone marrow is reinfused on day 0. Patients receive G-CSF SC every 12 hours beginning on day 1 and continuing until blood counts recover. If additional HGFs become available, they may be administered concurrently with G-CSF. Quality of life is assessed at baseline and then at 6, 12, and 24 months after transplantation. Patients are followed at 1 and 3 months, every 3 months through year 2, every 4 months through year 5, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 80 patients (20 for regimen A and 60 for regimen B) will be accrued for this study.
Study Type ICMJE	Interventional
Study Phase	Phase 2
Study Design ICMJE	Masking: None (Open Label); Primary Purpose: Treatment
Condition ICMJE	Lymphoma
Intervention ICMJE	Biological: filgrastim; Biological: sargramostim; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Procedure: autologous bone marrow transplantation; Procedure: bone marrow ablation with stem cell support; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Study Arms	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status ICMJE	Completed
Enrollment ICMJE	Not Provided
Original Enrollment ICMJE	Not Provided
Actual Study Completion Date	June 2003
Actual Primary Completion Date	June 2003 (Final data collection date for primary outcome measure)
Eligibility Criteria ICMJE	DISEASE CHARACTERISTICS: One of the following diagnoses: Histologically proven recurrent non-Hodgkin's lymphoma Previously in complete remission (CR) Refractory or recurrent intermediate-grade lymphoma (IGL) or high-grade immunoblastic lymphoma (IBL) meeting 1 of the following conditions: In partial remission (PR) or CR to and currently enrolled on the MSKCC standard dose salvage regimen with ifosfamide, carboplatin, and etoposide (ICE) In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of cyclophosphamide, mechlorethamine, vincristine, procarbazine, and prednisone (C-MOPP)) No prior ifosfamide Low-grade lymphoma In second or greater remission or chemosensitive relapse No HLA identical sibling donor available IGL or IBL In first CR Poor prognosis, defined by age-adjusted international index of 3 or 4 based on lactic dehydrogenase, number of extranodal sites, stage, and performance status; Adequate bone marrow cellularity; No lymphoblastic or small noncleaved cell lymphoma; Ineligible for total body irradiation (TBI) phase of study if prior radiotherapy dose precludes the use of TBI NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma.However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: Physiologic 18 to 65 Performance status: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL (if no history of Gilbert's disease); No chronic active or persistent hepatitis; Hepatitis B positivity allowed provided that the following conditions are met: Bilirubin same as above* SGPT no greater than 500 IU/L* Alkaline phosphatase no greater than 2 times normal* NOTE: * In the absence of liver involvement by lymphoma Renal: Creatinine no greater than 1.5 mg/dL OR; Creatinine clearance at least 60 mL/min; No history of chronic renal insufficiency Cardiovascular: LVEF at least 50% by echocardiogram or MUGA scan; No myocardial infarction within the past 6 months; No unstable angina; No arrhythmia other than chronic atrial fibrillation Pulmonary: DLCO at least 50% predicted (corrected for hemoglobin and alveolar ventilation) Other: HIV negative; No uncontrolled infection; No other malignancy within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy; Not specified Chemotherapy; See Disease Characteristics Endocrine therapy; Not specified Radiotherapy; See Disease Characteristics Surgery; Not specified
Sex/Gender	Sexes Eligible for Study: All
Ages	18 Years to 65 Years (Adult)
Accepts Healthy Volunteers	No
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries ICMJE	United States
Removed Location Countries
Administrative Information
NCT Number ICMJE	NCT00002697
Other Study ID Numbers ICMJE	95-072; CDR0000064483 ( Registry Identifier: PDQ (Physician Data Query) ); NCI-V95-0784
Has Data Monitoring Committee	Not Provided
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Not Provided
Study Sponsor ICMJE	Memorial Sloan Kettering Cancer Center
Collaborators ICMJE	Not Provided
Investigators ICMJE	Study Chair: Craig Moskowitz, MD Memorial Sloan Kettering Cancer Center
PRS Account	Memorial Sloan Kettering Cancer Center
Verification Date	July 2013
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP